...
首页> 外文期刊>Journal of Ovarian Research >Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair
【24h】

Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair

机译:Let-7e通过抑制DNA双链断裂修复使上皮​​性卵巢癌对顺铂敏感

获取原文
   

获取外文期刊封面封底 >>

       

摘要

BackgroundResistance to platinum-based chemotherapy remains a great challenge for ovarian cancer treatment. The human let-7 family contains 13 members located on nine different chromosomes, and most members have been implicated in the modulation of drug sensitivity in cancers. Our previous study showed that deregulation of let-7e in epithelial ovarian cancer (EOC) promoted the development of resistance to cisplatin. In the present study, we aimed to investigate the underlying mechanism and further evaluate the clinical value of let-7e in predicting chemo-response and prognosis in EOC. ResultsIn situ hybridization assays revealed a significantly decreased expression of let-7e in chemo-resistant EOC tissues compared with chemo-sensitive cases. Transfection with let-7e agomir sensitized EOC cells to cisplatin, down-regulated BRCA1 and Rad51 expression, and repressed the repair of cisplatin-induced DNA double strand break, while let-7e inhibitor exerted the opposite effects. In human EOC tissues, BRCA1 and Rad51 levels were increased in the chemo-resistant group compared with the sensitive group and were negatively correlated with let-7e. Low let-7e and high Rad51 were significantly associated with poor progression-free survival and overall survival and multivariate regression analyses showed that let-7e was an independent predictor for overall survival and chemotherapy response in EOC. Receiver operating characteristic analysis indicated that let-7e level was highly predictive of resistance to platinum-taxane chemotherapy with an area under the curve of 0.826. ConclusionsIn EOC, low let-7e leads to activation of BRCA1 and Rad51 expression and subsequent enhancement of DSB repair, which in turn results in cisplatin-resistance. Let-7e is a potential predictor for survival and chemo-response in EOC and re-expression of let-7e might be an effective strategy for overcoming chemo-resistance.
机译:背景铂类化学疗法的耐药性仍然是卵巢癌治疗的巨大挑战。人let-7家族包含位于9个不同染色体上的13个成员,并且大多数成员与癌症中药物敏感性的调节有关。我们先前的研究表明,上皮性卵巢癌(EOC)中let-7e的失控促进了对顺铂耐药性的发展。在本研究中,我们旨在研究其潜在机制,并进一步评估let-7e在预测EOC的化学反应和预后方面的临床价值。结果与化学敏感病例相比,原位杂交试验显示,let-7e在耐药化学EOC组织中的表达明显降低。 let-7e agomir转染使EOC细胞对顺铂敏感,下调BRCA1和Rad51表达,并抑制顺铂诱导的DNA双链断裂的修复,而let-7e抑制剂则发挥相反的作用。在人类EOC组织中,与敏感组相比,化疗耐药组的BRCA1和Rad51水平升高,与let-7e呈负相关。低let-7e和高Rad51与不良的无进展生存期和总体生存率显着相关,多元回归分析表明,let-7e是EOC总体生存率和化疗反应的独立预测因子。接受者的工作特征分析表明,let-7e水平可高度预测其对铂-紫杉烷化疗的耐药性,其曲线下面积为0.826。结论在EOC中,低let-7e导致BRCA1和Rad51表达的激活以及随后DSB修复的增强,进而导致顺铂耐药。 Let-7e是EOC存活和化学反应的潜在预测因子,而let-7e的重新表达可能是克服化学耐药性的有效策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号